Tandem Diabetes Care COO converts 3,637 stock units

The RSUs were awarded under the 2023 Plan, with remaining units vesting in eight equal quarterly installments subject to its terms.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Tandem Diabetes Care Inc.’s EVP & Chief Operating Officer, Jean-Claude Kyrillos, reported converting 3,637 restricted stock units into 3,637 common shares on October 15, 2026. The issuer withheld 1,926 shares for tax withholding, reported at $16.52 per share; the footnote states that no shares were sold. His reported post-transaction RSU position was 10,908 shares.

Insider Trade Summary

3,637 shares exercised/converted

Exercise 3 txns

Insider Kyrillos Jean-Claude

Role EVP & Chief Operating Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit ^{F2, F3, F4}	3,637	$0.00	$0.00
Exercise	Common Stock	3,637	$0.00	$0.00
Tax Withholding	Common Stock ^F1	1,926	$16.52	$32K

Holdings After Transaction: Restricted Stock Unit — 10,908 contracts (Direct); Common Stock — 32,001 shares (Direct)

Footnotes (4)

F1. Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold.
F2. Awarded on July 15, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
F3. Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
F4. One-third of the RSUs granted on July 15, 2024 vested on July 15, 2025, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan.

Key Figures

RSUs converted: 3,637 RSUs Common shares acquired: 3,637 shares Shares withheld for tax withholding: 1,926 shares +2 more

5 metrics

RSUs converted 3,637 RSUs October 15, 2026

Common shares acquired 3,637 shares October 15, 2026

Shares withheld for tax withholding 1,926 shares October 15, 2026

Price per share $16.52 per share Shares withheld for tax withholding on October 15, 2026

Post-transaction RSU position 10,908 shares Following the October 15, 2026 transaction

Key Terms

restricted stock units (RSUs), contingent right, 2023 Long-Term Incentive Plan, tax withholding requirements

4 terms

restricted stock units (RSUs) financial

"vesting of restricted stock units (RSUs)"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

contingent right financial

"Each RSU represents a contingent right"

2023 Long-Term Incentive Plan financial

"pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan"

tax withholding requirements financial

"to satisfy tax withholding requirements"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TNDM shares did the COO acquire and have withheld?

On October 15, 2026, Jean-Claude Kyrillos acquired 3,637 common shares through an RSU conversion, while the issuer withheld 1,926 shares for tax withholding at $16.52 per share. The footnote states that no shares were sold.

When were Jean-Claude Kyrillos’s TNDM RSUs awarded, and how did they vest?

The RSUs were awarded on July 15, 2024, under Tandem Diabetes Care’s 2023 Long-Term Incentive Plan. One-third vested on July 15, 2025, and the remaining RSUs vest in eight equal quarterly installments thereafter, subject to the plan’s terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/19/2026 - 06:20 PM EDT Accepted by SEC EDGAR 10/19/2026 - 06:20 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kyrillos Jean-Claude

(Last)

(First)

(Middle)

12400 HIGH BLUFF DRIVE

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TANDEM DIABETES CARE INC [ TNDM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP & Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/15/2026		M		3,637	A	$0	33,927	D
Common Stock	10/15/2026		F⁽¹⁾		1,926	D	$16.52	32,001	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit⁽²⁾	⁽³⁾	10/15/2026		M			3,637	⁽⁴⁾	⁽⁴⁾	Common Stock	3,637	$0	10,908	D

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold.

2. Awarded on July 15, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

3. Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

4. One-third of the RSUs granted on July 15, 2024 vested on July 15, 2025, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan.

Remarks:

	/s/ Jerilyn Laskie, Attorney-in-Fact for Jean-Claude Kyrillos	10/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR